In this study, we demonstrate that although CDK4/6 inhibition does not potentiate the metabolic effects of BRAF and MEK inhibition in melanoma, there is a significant upregulation of mitochondrial activity following CDK4/6 inhibition. This evidence concerns the gene MAP2K7 and melanoma.